DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1575)

TreatmentTrends: Hepatitis C (EU) 2013

TreatmentTrends® Hepatitis C (HCV) in the E5 is a report that covers the use of agents for the treatment of HCV. This annual report focuses on current and future use of leading interferon and development products, patient market share, perceived strengths and weaknesses of the key brands, barriers to broader usage, sales force performance and perceived value of manufacturers’ patient assistance programs in France, Germany, Italy Spain and the UK. In addition, assessment of the potential impact of agents in develop-ment is included.
TreatmentTrends® are syndicated report series that provide longitudinal information on market dynamics. They pro-vide insight into practice patterns, attitudes and perceptions, and current and projected use of various products. They evaluate per-ceived product advantages and disadvantages, as well as sales and messaging efforts of key market players.

Questions Answered in This Report:

  • Quantify the HCV case load by patient type/severity, source of patient origination, the non-responder patient population, and the prevalence of anti-viral treatment

  • Quantify the non-treated, “warehouse” Hep C population and changes in the number of HCV patients treated following introduction of the protease inhibitors

  • Quantify current and anticipated future patient share of the pegylated interferons and protease inhibitors; understand perceived differences and preferences in HCV for: pegylated interferon-alpha-2a vs 2b (Pegasys vs Pegintron) and the new protease inhibitors (telaprevir and boceprevir)

  • Evaluate physicians’ attitudes and perceptions regarding: the importance of product attributes, performance of existing therapies against these attributes, and the performance of Boceprevir and Telaprevir

  • Understand how and why interferon use is expected to shift among physicians in the next six months for HCV; identify drivers and barriers to product adoption and broader usage

  • Evaluate the interest in new products in development (PSI-7977, BMS-790052 and TMC435 etc.) and assess how these products may impact the market


Sample Frame & Methodology:

Each report will include responses from a random sample of:

- 200 gastroenterologists and 50 hepatologists

- The physicians are recruited from the UK (n=50), Germany (n=50), Italy (n=50), Spain (n=50) and France (n=50)

The survey is quantitative with open-ended questions for qualitative feedback

To qualify for participation, physicians have to meet the following criteria:

- Board Certified in their specialty

- In practice between 2 and 30 years

- Managing a minimum of 25 patients with HCV

- Spend at least 75% of their profes-sional time in clinical practice

- Not on a national advisory board for any of the profile companies


- The complete report, including key findings in PowerPoint format

- Statistically significant differences of the results, where appropriate, will be highlighted

- A complete set of frequency tables, summary statistics, and cross-tabulations

- Onsite or webcast presentations are available upon request at no additional charge

- Clients purchasing prior to fielding will have the opportunity to include up to three proprietary questions in each quantitative wave of research

Product Coverage:

Approved: Incivek, Victrelis, Pegasys, PegIntron, and ribavirin

In development: faldaprevir, daclatasvir, sime-previr, and sofosbuvir

Related 2013 Reports:

- TreatmentTrends®: Hepatitis C (US)

- ChartTrends®: Hepatitis C (US)

- LaunchTrends®: Sofosbuvir (US)

- PatientTrends®: Hepatitis C (US)